Drug Trial Radar · NCT01347866
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Oct 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
105
Actual
Start
Oct 2011
Primary completion
Dec 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 4, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
After the fourth protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (oral MEK inhibitor) plus PF-05212384 (intravenous PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan. The study will assess safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer. Once the maximum tolerated doses are identified, further assessment of these combinations will be done in patients with previously treated metastatic colorectal or pancreatic cancer for the PF-05212384 plus irinotecan arm and in patients with ovarian cancer or KRAS mutated non small cell lung cancer for the combination of PF-05212384 plus PD-0325901.
Conditions
- Advanced Cancer
Interventions
PF-05212384Drug
PF-05212384 intravenous infusion weekly starting at 110 mg.
PD-0325901Drug
PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
PF-05212384Drug
PF-05212384 intravenous infusion weekly starting at 95 mg.
irinotecanDrug
Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Dose-Limiting Toxicities (DLTs) in First Cycle (28 Days)Time frame: Baseline up to 28 days
Locations
18 sites in 4 countries. Site status is shown where the registry gives one.
Ronald Reagan UCLA Medical Center
Los Angeles, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCLA Medical Center
Los Angeles, California
UCLA Oncology Center
Los Angeles, California
Santa Monica - UCLA Medical Center and Orthopaedic Hospital
Santa Monica, California
UCLA Santa Monica Hematology Oncology
Santa Monica, California
Anschutz Cancer Pavilion
Aurora, Colorado
University of Colorado Denver (CTRC)
Aurora, Colorado
University of Colorado Hospital Anschutz Inpatient Pavilion
Aurora, Colorado
University of Colorado Hospital
Aurora, Colorado
Medical University of South Carolina, Hollings Cancer Center
Charleston, South Carolina
Medical University of South Carolina
Charleston, South Carolina
MUSC, Investigational Drug Services
Charleston, South Carolina
MUSC Health East Cooper
Mt. Pleasant, South Carolina
MUSC Specialty Care-North
North Charleston, South Carolina
Princess Margaret Hospital
Toronto, Ontario, Canada
Ospedale San Raffaele
Milan, Italy
Hospital General Vall d'Hebron
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.